CS Diagnostics Corp (CSDX) 주가 예측

CS Diagnostics Corp. is a medical distribution company that provides the advancing patient care through innovative solutions. The company is headquartered in Neuss, Nordrhein-Westfalen. The company went IPO on 2005-02-23. The firm is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. The company is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. The company includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.